Phase 2 Oesophageal Cancer Trial, Recruiting NCT07217938 Sponsor: Peter MacCallum Cancer Centre, Australia Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT07217938
Recruiting Phase 2 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have signed a written consent form specific to this trial
  • People who are 18 years of age or older at the time of screening
  • People who received radiation therapy or chemoradiation treatment aimed at curing cancer in the throat, voice box, or surrounding areas, at least 2 years before screening
  • People who have been found to have moderate-to-severe swallowing difficulties caused by radiation, identified through a specific swallowing test (called a VFSS) carried out within the last 12 months
  • People whose kidneys are functioning at an adequate level, as determined by a blood test result (confirm with trial site)
  • People whose liver is functioning at an adequate level, based on specific blood test results (confirm with trial site)
  • People who are generally able to carry out daily activities, with limited or no restrictions due to their health condition, as measured by a standard medical scoring system (confirm with trial site)

Who may not be able to join:

  • People with a known allergy or sensitivity to the medication pravastatin or any of its ingredients
  • People who have been diagnosed with a muscle weakness condition (such as myasthenia)
  • People who have had surgery on the head or neck, beyond minor procedures like a biopsy or a neck dissection after cancer treatment
  • People who currently have an active cancer diagnosis
  • People who are currently taking any statin medication
  • People who are currently taking long-term steroids or certain other medications listed by the trial (confirm with trial site)
  • People with a history of severe heart failure, muscle side effects from previous statin or fibrate medications, or inherited muscle disease
  • People with a known medical condition that may already affect their ability to swallow, such as a stroke, a neurological condition, or a tracheostomy
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +61 (03) 8559 5220

Australian sites

Peter MacCallum Cancer Centre, Melbourne, Victoria
+61 38559 5220

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Peter MacCallum Cancer Centre, Australia
Registry
ClinicalTrials.gov
Start date
5 December 2025
Est. completion
1 October 2028

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Feasibility of a 12 month trial investigating the use of pravastatin to treat radiation-associated dysphagia; Preliminary evidence of efficacy of the pravastatin to treat radiation-associated dysphagia

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov